BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, May 26, 2026
Home » The week's biggest gainers and losers

The week's biggest gainers and losers

May 28, 2019

Article reprints

To read more on related topics, click on one of the words below.

BioWorld

    • Related Articles

      The week's biggest gainers and losers

      The week's biggest gainers and losers

      The week's biggest gainers and losers

    Popular Stories

    • Today's news in brief

      BioWorld
      BioWorld briefs for May 22, 2026.
    • Brain and DNA

      Sangamo presents primate data for prion suppressor ST-506

      BioWorld Science
      Sangamo Therapeutics Inc. discussed gene regulation approaches for neurodegenerative diseases when presenting findings on their clinical candidate ST-506 for the...

    • TREM2 agonists detailed in Pfizer patent

      BioWorld Science
      Pfizer Inc. has reported new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for the treatment of neurodegeneration.

    • Selection Therapeutics identifies new Kv1.3 blockers

      BioWorld Science
      Selection Therapeutics GmbH has discovered new potassium voltage-gated channel subfamily A member 3 (KCNA3; Kv1.3) blockers potentially useful for the treatment...

    • Ignis Therapeutics synthesizes new muscarinic M4 receptor PAMs

      BioWorld Science
      Ignis Therapeutics (Suzhou) Co. Ltd. has patented new muscarinic M4 receptor positive allosteric modulators (PAMs) potentially useful for the treatment of...
    • BioWorld
      • Today's news
      • Analysis and data insight
      • Clinical
      • Data Snapshots
      • Deals and M&A
      • Financings
      • Medical technology
      • Newco news
      • Opinion
      • Regulatory
    • BioWorld Science
      • Today's news
      • Biomarkers
      • Cancer
      • Conferences
      • Endocrine/metabolic
      • Immune
      • Infection
      • Neurology/psychiatric
      • NME Digest
      • Patents
    • BioWorld Asia
      • Today's news
      • Analysis and data insight
      • Australia
      • China
      • Clinical
      • Deals and M&A
      • Financings
      • Newco news
      • Regulatory
      • Science
    • More
      • About
      • Advertise with BioWorld
      • Archives
      • Article reprints and permissions
      • Contact us
      • Cookie policy
      • Copyright notice
      • Data methodology
      • Infographics: Dynamic digital data analysis
      • Index insights
      • Podcasts
      • Privacy policy
      • Share your news with BioWorld
      • Staff
      • Terms of use
      • Topic alerts
    Follow Us

    Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing